
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…

Recording of virtual meeting – Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention…

COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An…

TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear…

Lo Studio ATLAS: uno studio clinico per le persone che vogliono contribuire alla ricerca sulla SOD1 nella SLA
Lo studio clinico valuta l’efficacia e la sicurezza di un farmaco sperimentale…

Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…

TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…

USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…

Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested…

A road map for digital health care technology in MND
The COVID-19 pandemic has had an important impact on the development and…